New Delhi: A Public Interest Litigation (PIL) petition has been filed in the Supreme Court against the Directors of Ranbaxy Laboratories for allegedly manufacturing and selling adulterated drugs in India.
The PIL, which comes in the wake of the Indian pharma major being fined $500 million by the US Food and Drug Administration (US FDA) for making and selling “adulterated” drugs, was filed on Wednesday by advocate Manoharlal Sharma.
The petitioner sought prosecution of all directors of the company and a bar on any further sale of drugs manufactured by Ranbaxy and also seizure of the entire property of the directors of the firm.
He also sought action against the Central Drug Standards Control Organisation (CDSCO) for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the US FDA investigation against the company. [Source: Hindu]